VINC Stock Overview
A clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Vincerx Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.26 |
| 52 Week High | US$9.37 |
| 52 Week Low | US$0.24 |
| Beta | 1.27 |
| 11 Month Change | -32.63% |
| 3 Month Change | -67.59% |
| 1 Year Change | -60.01% |
| 33 Year Change | -97.56% |
| 5 Year Change | n/a |
| Change since IPO | -97.26% |
Recent News & Updates
Recent updates
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely
Aug 21
Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Jul 18Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Mar 30Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Sep 22Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?
Jun 24Vincerx Pharma doses first patient in early-stage VIP152 cancer study
Jun 03Shareholder Returns
| VINC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.2% | 4.0% | 2.0% |
| 1Y | -60.0% | 18.0% | 32.4% |
Return vs Industry: VINC underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: VINC underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| VINC volatility | |
|---|---|
| VINC Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VINC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VINC's weekly volatility has decreased from 23% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 42 | Ahmed Hamdy | vincerx.com |
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies.
Vincerx Pharma, Inc. Fundamentals Summary
| VINC fundamental statistics | |
|---|---|
| Market cap | US$8.56m |
| Earnings (TTM) | -US$27.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs VINC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VINC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.03m |
| Earnings | -US$27.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VINC perform over the long term?
See historical performance and comparison